Last month Roche announced the "initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome."
This new clinical trial, the first of its kind, targets adults age 18-30.
I think it is exciting that clinical trials for Down syndrome are now being thought of as worthwhile and something to look in to.
It'll be interesting to see the results of this study and what this could mean in the future for individuals with Down syndrome.
Grab This Button
Tuesday, October 18, 2011
Subscribe to:
Post Comments (Atom)
1 comment:
I am not leaving a comment about the trials but just wanted to let you know that I just found your blog and I love it. I also have a little one with Ds she is 2, and I am always looking for blogs that are a little ahead of us.
Post a Comment